ASH News Daily 2013 - Day 2 - (Page A-11)
1.5"
BECAUSE THE CONSEQUENCES
CAN BE DEVASTATING1-4
aHUS
70% of aHUS* patients (with the most common mutation ) die, require dialysis,
of aHUS* patients (with the most common mutation†) die, require dialysis,
or have permanent renal damage within 1 year
or have permanent renal damage within 1 year4
* In aHUS, uncontrolled complement activation leads to systemic thrombotic microangiopathy (TMA)4,12-16
* 33% to 40% of all patients die or progress to end-stage renal disease with the fi rst clinical manifestation4,12
* Plasma exchange/infusion (PE/PI) does not address chronic, uncontrolled
complement activation, the underlying cause of TMA in aHUS12,16-22
- There have been no well-controlled trials showing PE/PI to be either safe
or effective in the treatment of aHUS23
* Differential diagnosis of aHUS is warranted3,10
*aHUS = atypical hemolytic uremic syndrome.
†CFH mutations = most common population.
Visit Alexion booth #3521 at ASH, December 7-10, 2013,
Ernest N. Morial Convention Center, New Orleans, LA, for more information.
For more information about PNH and aHUS, visit
www.PNHSource.com and www.aHUSSource.com
F:10.75"
Y75
Y50
Y25
R100
R75
R50
R25
G100
G75
G50
G25
B100
B75
B50
B25
© 2013, Alexion Pharmaceuticals, Inc. All rights reserved. 1013.1.4.0.075
10/31/13 12:58 PM
T: 14"
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2
Table of Contents
ASH News Daily 2013 - Day 2
https://www.nxtbookmedia.com